RSV - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

New respiratory syncytial virus vaccine shows promise in Phase I trial

Micrograph of human respiratory syncytial virus virions (colourised blue) and labelled with anti-RSV F protein/gold antibodies (colourised yellow). Credit: NIAID.